A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance — Decera Clinical Education Oncology Podcast

In this episode, listen to Matthew S. Davids, MD, MMSc, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:

Contemporary treatment paradigms for patients with CLL
Safety and efficacy of current regimens
Molecular testing, including when and how to test for BTK inhibitor resistance
Considering BTK inhibitor resistance when sequencing therapy

Program faculty:

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Leader, Lymphoma Program
Dana-Farber/Harvard Cancer Center
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Lindsey Roeker, MD
Assistant Attending
CLL Program Director
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Resources:
To review a CME-certified text activity and download slides associated with this podcast discussion, please visit the program page.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.